A group of investors is betting $217 million that a new drug company led by three Genentech alumni can break the frustrations of what, to now, has been a Sisyphean task: Finding treatments for the world’s most vexing neurodegenerative diseases, including... Read more »
In a hectic month for deals, product advances, and bogus NFL investigations, New England is taking time out to recognize emerging leaders in its tech and life sciences scene. Let’s get right to the highlights:
—The third annual NEVY awards,... Read more »
Catabasis Pharmaceuticals appeared headed for the Nasdaq a few years ago when it brought in some investors known better for backing public companies than biotech startups. The Cambridge, MA-based company has since done some strategic tinkering, however, and now finally appears... Read more »
The patient numbers keep growing for Sage Therapeutics, but, at least for now, the story is the same—its experimental epilepsy drug remains promising. Now comes the hard part: testing it in a big, randomized, placebo-controlled trial.
Cambridge, MA-based Sage (NASDAQ: SAGE... Read more »
Gelesis gobbled up some cash from private investors just a few months ago. But it looks like public investors don’t have the same type of appetite for the Boston startup’s hydrogel weight-loss pills.
According to research firm Renaissance Capital, Gelesis... Read more »
‘Tis high season for tech and innovation events in New England. Just this week we have the NEVYs, the MITX Awards, and Tech State House Day.
Now let’s talk about next month—and the next 20 years.
On June... Read more »
Selecta Biosciences looks to have found two new potential niches for its nanoparticle technology.
The Watertown, MA-based company is announcing two deals this morning. First, Selecta said that Sanofi has chosen to license a potential immunotherapy treatment for celiac disease, the... Read more »
An FDA advisory panel this afternoon recommended approval of a new combination treatment for cystic fibrosis from Vertex Pharmaceuticals, potentially paving the way for billions of dollars in future sales if the agency ultimately approves the drug.
The panel of outside... Read more »
To get the best view of the innovation taking place in a city, it helps to get down to the bottom, the foundation of each community’s ecosystem: the entrepreneurs themselves.
Thanks to our generous sponsors, Xconomy has been able to provide... Read more »